S
S. Deudon
Researcher at Novartis
Publications - 11
Citations - 837
S. Deudon is an academic researcher from Novartis. The author has contributed to research in topics: Breast cancer & Anaplastic lymphoma kinase. The author has an hindex of 5, co-authored 10 publications receiving 691 citations.
Papers
More filters
Journal ArticleDOI
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw,Tae Min Kim,Lucio Crinò,Cesare Gridelli,Katsuyuki Kiura,Geoffrey Liu,Silvia Novello,Alessandra Bearz,Oliver Gautschi,Tony Mok,Makoto Nishio,Giorgio V. Scagliotti,David R. Spigel,S. Deudon,Cheng Zheng,Serafino Pantano,Patrick Urban,Cristian Massacesi,Kalyanee Viraswami-Appanna,Enriqueta Felip +19 more
TL;DR: Ceritinib showed a significant improvement in median progression-free survival compared with chemotherapy and was compared with single-agent chemotherapy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy.
Journal ArticleDOI
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Fabrice Andre,Thomas Bachelot,Mario Campone,Florence Dalenc,Jose Perez-Garcia,Sara A. Hurvitz,Nicholas C. Turner,Hope S. Rugo,John W. Smith,S. Deudon,Michael M. Shi,Yong Zhang,Andrea Kay,Diana Graus Porta,A. Yovine,José Baselga +15 more
TL;DR: Dovitinib showed antitumor activity in FGFR-amplified breast cancer cell lines and may have activity in breast cancers with FGF pathway amplification.
Journal ArticleDOI
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy
Antonino Musolino,Mario Campone,Patrick Neven,Neelima Denduluri,Carlos H. Barrios,Javier Cortes,Kimberly L. Blackwell,Hatem Soliman,Zsuzsanna Kahán,Hervé Bonnefoi,Matthew Squires,Yong Zhang,S. Deudon,Michael M. Shi,Fabrice Andre +14 more
TL;DR: Dovitinib in combination with fulvestrant showed promising clinical activity in the FGF pathway–amplified subgroup, and the safety profile was consistent with the known safety profile of single-agent dovit inib.
Journal ArticleDOI
Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
G.V. Scagliotti,Tae Min Kim,L. Crinò,G. Liu,C. Gridelli,Silvia Novello,K. Kiura,Alessandra Bearz,Oliver Gautschi,Enriqueta Felip,Makoto Nishio,David R. Spigel,Tony Mok,Patrick Urban,S. Deudon,Cheng Zheng,Alice T. Shaw +16 more
Proceedings ArticleDOI
Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled study
Fabrice Andre,Patrick Neven,Antonino Musolino,Luciano Latini,M. Campone,J. Cortes,Carlos Barrios,Matthew Squires,Yunyu Zhang,S. Deudon,S Gogov,K. L. Blackwell +11 more
TL;DR: The objective of this study is to determine if dovitinib in combination with fulvestrant can improve outcomes in postmenopausal patients with endocrine resistant HER2-/HR+ breast cancer.